Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462927 · ClinicalTrials.gov registry record · Phase 2
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
A Phase 2 study, sponsored by MC2 Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03462927 is a Phase 2 study that has completed, run by MC2 Therapeutics. The registered enrollment target is 63 participants.
The verdict
NCT03462927, a Phase 2 study, has completed, sponsored by MC2 Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene \[CAL\]/betamethasone \[BDP\] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
Interventions
- DRUG MC2-01 Cream
- DRUG CAL/BDP combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2018-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03462927
The ClinicalTrials.gov registry entry for NCT03462927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MC2 Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MC2-01 Cream is the first listed.
NCT03462927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03462927 about?
NCT03462927 is a clinical study titled "A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream". This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene \[CAL\]/betamethasone \[BDP\] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
What is the current status of trial NCT03462927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-02-08. Estimated completion is 2018-08-04.
What interventions are being tested in trial NCT03462927?
The interventions under investigation include: MC2-01 Cream (DRUG), CAL/BDP combination (DRUG).
Who is sponsoring clinical trial NCT03462927?
This trial is sponsored by MC2 Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.